United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 4

Name: Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 4 comparison snapshot
Creator: Fliar BI Prism

A five-company pharmaceutical preparations cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 31 August 2026Not investment adviceRanked by Prism readiness

Readiness leaderCollegium Pharma · 55

Strongest available pathTango Therapeutics · +76.6%

Widest latest marginCollegium Pharma · 8.1%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1COLL · Nasdaq

Collegium Pharma

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2002Canton, Massachusetts$762.9M market cap

View full Companies Radar profile

55Moderate

Snapshot price$24.61as of page date

Monthly-close return+24.7%five-year window

FY2025 revenue$0.78BCOLLEGIUM PHARMACEUTICAL, INC

Net margin8.1%FY2025

P/E snapshot19.4xone ratio, not a verdict

Prism attention6.5%share across these five

Filing track recordRevenue, USD billions

+181.9%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 29.6%

52-week position1% through range

$24.46$50.79

News mentions459

Community mentions3partial coverage

U.S.-scope patents139

Prism InsightsWhat sits behind the readiness signal
Observed risk 4/100higher means more observed risk

Earnings signal68/100
Management stability90/100
Market position12/100
Capital-event signal78/100
Innovation pulse23/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 11 M&A involvements, 0 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 4 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2LXRX · Nasdaq

Lexicon Pharmaceuticals

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1995The Woodlands, Texas$1.00B market cap

View full Companies Radar profile

55Moderate

Snapshot price$2.25as of page date

Monthly-close return-53.2%five-year window

FY2024 revenue$0.01BLEXICON PHARMACEUTICALS, INC.

Net margin-3339.5%FY2024

P/E snapshot-11.8xone ratio, not a verdict

Prism attention22.2%share across these five

Filing track recordRevenue, USD billions

-77.4%

FY2018–FY2024 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -52.5%

52-week position74% through range

$1.03$2.68

News mentions1.6K

Community mentions50partial coverage

U.S.-scope patents1182

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal57/100
Management stability90/100
Market position6/100
Capital-event signal85/100
Innovation pulse27/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 3 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 11 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3TNGX · Nasdaq

Tango Therapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2017Cambridge, Massachusetts$3.85B market cap

View full Companies Radar profile

55Moderate

Snapshot price$22.84as of page date

Monthly-close return+76.6%five-year window

FY2025 revenue$0.06BTango Therapeutics, Inc.

Net margin-162.9%FY2025

P/E snapshot-14.0xone ratio, not a verdict

Prism attention9.5%share across these five

Filing track recordRevenue, USD billions

+68.4%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 13.9%

52-week position59% through range

$6.25$34.39

News mentions667

Community mentions3partial coverage

U.S.-scope patents122

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal74/100
Management stability90/100
Market position8/100
Capital-event signal83/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 4 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 4 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4TNXP · Nasdaq

Tonix Pharma

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2007New York City, New York$241.8M market cap

View full Companies Radar profile

55Moderate

Snapshot price$14.10as of page date

Monthly-close return-100.0%five-year window

FY2025 revenue$0.01BTonix Pharmaceuticals Holding Corp.

Net margin-946.2%FY2025

P/E snapshot-1.8xone ratio, not a verdict

Prism attention14.2%share across these five

Filing track recordRevenue, USD billions

+68.7%

FY2023–FY2025 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 29.9%

52-week position21% through range

$9.40$31.55

News mentions997

Community mentions0partial coverage

U.S.-scope patents325

Prism InsightsWhat sits behind the readiness signal
Observed risk 8/100higher means more observed risk

Earnings signal70/100
Management stability90/100
Market position8/100
Capital-event signal92/100
Innovation pulse15/100

Management signal

No leadership-churn flag in the model; 2 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 1 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 3 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5BHC · NYSE

Solta

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1999Hayward, California$2.38B market cap

View full Companies Radar profile

54Moderate

Snapshot price$6.37as of page date

Monthly-close return-77.1%five-year window

FY2025 revenue$10.27BBausch Health Companies Inc.

Net margin1.5%FY2025

P/E snapshot1.5xone ratio, not a verdict

Prism attention47.6%share across these five

Filing track recordRevenue, USD billions

+21.7%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 5.0%

52-week position56% through range

$4.33$8.00

News mentions3.3K

Community mentions18partial coverage

U.S.-scope patents170

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal65/100
Management stability90/100
Market position14/100
Capital-event signal67/100
Innovation pulse22/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 14 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 1 lifetime product-launch events, 1 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Tango Therapeutics

+76.6%

Collegium Pharma

+24.7%

Lexicon Pharmaceuticals

-53.2%

Solta

-77.1%

Tonix Pharma

-100.0%

Latest revenue

USD billions, official filing scope shown on each company card.

Solta

$10.27B

Collegium Pharma

$0.78B

Tango Therapeutics

$0.06B

Tonix Pharma

$0.01B

Lexicon Pharmaceuticals

$0.01B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Collegium Pharma

8.1%

Solta

1.5%

Tango Therapeutics

-162.9%

Tonix Pharma

-946.2%

Lexicon Pharmaceuticals

-3339.5%

Prism news attention

Normalized share across these five names; attention is not quality.

Solta

47.6%

Lexicon Pharmaceuticals

22.2%

Tonix Pharma

14.2%

Tango Therapeutics

9.5%

Collegium Pharma

6.5%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Solta leads the conversation

It holds 47.6% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $10.27B.

Price path

Tango Therapeutics leads the available price paths

Its monthly-close return is +76.6% for the five-year window. At the other end, Tonix Pharma is -100.0% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Collegium Pharma has the widest latest margin

Its FY2025 net margin is 8.1%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Tango Therapeutics shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -14.0x while its five-year window price return is +76.6%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · LXRX

Lexicon Pharmaceuticals

1,555available Prism news records

Prism top themes

Price action & investor response

Capital allocation & transactions

Earnings & financial performance

Leadership & governance

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-30.2%180 latest 12m vs 258 prior 12m

Machine-classified coverage tone

90.7% positive+0.9 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 20stock price 19share price 12diabetes kidney protection 12company valuation 10neuropathy screening diabetes 9nerve damage diabetes 9peripheral neuropathy treatment 9

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-20–2026-06-01 · trend and themes shown through 2026-06

Areas of research · TNXP

Tonix Pharma

997available Prism news records

Prism top themes

Price action & investor response

Macro demand & rates

Legal, arbitration & regulatory

Capital allocation & transactions

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-41.0%144 latest 12m vs 244 prior 12m

Machine-classified coverage tone

95.7% positive+7.4 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 28stock price 17fibromyalgia syndrome techniques 14market momentum 14vaccine formulation 13market rally 12subunit vaccines 11viral vector vaccines 9

Keyword tag occurrences in available Prism news records.

Coverage: 2011-10-14–2026-06-12 · trend and themes shown through 2026-06

Areas of research · BHC

Solta

3,339available Prism news records

Prism top themes

Price action & investor response

103

Earnings & financial performance

Capital allocation & transactions

Leadership & governance

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-22.3%421 latest 12m vs 542 prior 12m

Machine-classified coverage tone

94.3% positive+1.5 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

generic drug approval 37stock performance 27earnings report 24quarterly financials 16financial report 15company valuation 15annual earnings 15quarterly results 14

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-08–2026-06-11 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

LXRX

Lexicon Pharmaceuticals

50 mentions

Stock and valuation

Products, pricing and logistics

Workplace and hiring

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 50 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

COLL

Collegium Pharma

through 2026-04-18

Earnings releases 31Leadership changes 9M&A 7Company announcements 5Business contracts 2

2026-04-18
Company announcements
Collegium guided to total revenues of $805 million to $825 million, representing 4% year-over-year growth.
2026-04-17
M&A
Collegium is acquiring AZSTARYS, related intellectual property, and global rights from Corium, a private company, for $650 million upfront.
2026-04-15
Earnings releases
Financial Results for Quarter Ended December 31, 2025 Product revenues, net were $205.4 million for the 2025 Quarter, compared to $181.9 million for the quarter ended December 31, 2024 (the 2024 Quarter), representing a 13% increase year-over-year. GAAP net income for the 2025 Quarter was $17.0 million, with $0.54 GAAP earnings per share (basic) and $0.46 GAAP earnings per share (diluted), compared to GAAP net income for the 2024 Quarter of $12.5 million, with $0.39 GAAP earnings per share (basic) and $0.36 GAAP earnings per share (diluted).

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

LXRX

Lexicon Pharmaceuticals

through 2026-02-06

Leadership changes 16Company announcements 12Earnings releases 12Asset acquisitions 1Business contracts 1

2026-02-06
Company announcements
Lexicon Pharmaceuticals, Inc. (“Lexicon”) today announced the closing of its previously announced underwritten public offering of 32,000,000 shares of its common stock, par value $0.001, and concurrent private placement of 22,400,000 shares of common stock and 367,145 shares of series b convertible preferred stock (the “Series B Convertible Preferred Stock”).
2026-02-06
Asset acquisitions
Director Invus Global Management, Llc bought 1,538,462 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The shares were acquired at an average cost of $1.30 per share, for a total transaction of $2,000,000.60.
2026-02-02
Listing / IPO
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the closing of its previously announced underwritten public offering of 32,000,000 shares of its common stock, par value $0.001, and concurrent private placement of 22,400,000 shares of common stock and 367,145 shares of series b convertible preferred stock (the “Series B Convertible Preferred Stock”). The shares of common stock offered pursuant to the public offering were sold at a public offering price of $1.30 per share and the shares of preferred stock were sold at a price of $65 per share.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

TNGX

Tango Therapeutics

through 2026-04-27

Earnings releases 7Leadership changes 4Company announcements 2Listing / IPO 1

2026-04-27
Leadership changes
Publicly traded clinical stage biotech Tango Therapeutics developing precision cancer medicines, announced key leadership appointments to support its first potential regulatory approval in pancreatic cancer for vopimetostat, a highly potent and selective PRMT5 inhibitor. Effective April 15, Matthew Gall became chief financial officer, who was previously CFO Kalaris Therapeutics and iTeos Therapeutics, and held finance, business development, and corporate strategy roles at Sarepta Therapeutics, Celgene, and Gilead Sciences.
2026-02-06
Earnings releases
Based on Tango Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $53.81 million and a net profit of $15.88 million.
2025-09-03
Listing / IPO
Tango Therapeutics danced into the public stock market almost four years ago when it merged with BCTG Acquisition Corp.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

TNXP

Tonix Pharma

through 2026-03-03

Earnings releases 11Leadership changes 5Company announcements 3Listing / IPO 3Regulatory 3

2026-03-03
Regulatory
Tonix Pharmaceuticals Holding Corp. has received approval from Nasdaq to transfer the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market.
2025-12-11
Leadership changes
Staying in the medical industry, Tonix Pharmaceuticals has named Irina Ishak as general counsel, leading the company’s legal, corporate governance and compliance functions.
2025-11-10
Earnings releases
Net product revenue for the three months ended September 30, 2025 was approximately $3.3 million, compared to $2.8 million for the same period in 2024; revenue reflected combined net sales of Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray).

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

BHC

Solta

through 2025-12-01

M&A 4

2025-12-01
M&A
Along with its global aesthetic business, Solta Medical, today announced the successful completion of the acquisition of Wuhan Shibo Zhenmei Technology Co., Ltd., consisting of the Shibo group's aesthetics distribution business. Effective December 1, 2025, Wuhan Shibo Zhenmei Technology Co., Ltd. became a wholly owned subsidiary of Solta Medical in China, assuming full responsibility for the distribution of Solta Medical's products, including Thermage® FLX, as well as other aesthetic devices in the Chinese market.
2025-12-01
M&A
today announced the successful completion of the acquisition of Wuhan Shibo Zhenmei Technology Co., Ltd., consisting of the Shibo group's aesthetics distribution business.
2025-02-14
M&A
Solta Medical (Hayward, California), a medical aesthetics company, said it has completed its acquisition of Aesthera (Pleasanton, California) for $5.25 million in Solta common stock and cash, with potential additional base line milestones of $750,000 for a total consideration of $6 million.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence

2011 extracted base$66.70B

2016 extracted forecast$42.00B–$70.00B

Implied source CAGR9.5%

Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records

Latest 12m volume+3.4%24052 vs 23272 records

Positive classified tone65.3%+6.0 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies

6,223

snowstorm and blizzard alerts

6,121

pharmaceutical marketing and sales strategies

6,014

winter weather preparedness

5,925

generic drug development and market trends

3,700

healthcare economics and market access

3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 16–23. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 31 August 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Collegium Pharma leads the readiness ranking

Its Prism readiness score is 55/100, the highest in this five-company comparison.

Open Collegium Pharma in Companies Radar

Scale and margin leadership sit with Solta and Collegium Pharma

Solta has the largest displayed latest revenue at $10.27B; Collegium Pharma has the widest displayed latest margin at 8.1%.

Open Solta in Companies Radar Open Collegium Pharma in Companies Radar

Comparisons

Strongest versus weakest available price path

Tango Therapeutics is +76.6% for its five-year window; Tonix Pharma is -100.0% for its five-year window.

Open Tango Therapeutics in Companies Radar Open Tonix Pharma in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $10.27B for Solta to $0.01B for Lexicon Pharmaceuticals. Entity and filing-period labels remain visible on the company cards.

Open Solta in Companies Radar Open Lexicon Pharmaceuticals in Companies Radar

Anomalies

Solta has the widest attention-readiness rank gap

It ranks #1 by measured news attention (47.6%) and #5 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Solta in Companies Radar

Tonix Pharma shows a price-operating divergence to inspect

Its displayed filing-revenue change is +68.7% while its available monthly-close return is -100.0%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Tonix Pharma in Companies Radar

Explanations

Attention measures coverage volume, not quality

Solta's 47.6% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Solta in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Collegium Pharma's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 55/100 score.

Open Collegium Pharma in Companies Radar

Stress-test the largest divergence before forming a view

Compare Tonix Pharma's profile with Tango Therapeutics's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Tonix Pharma in Companies Radar Open Tango Therapeutics in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.